Jazz Pharmaceuticals (JAZZ)

• Market cap: $7.48B
• 1 day: -0.42%
• 5 days: 0.73%
• 1 month: -0.49%
• 3 months: 13.43%
• 6 months: 12.66%
• Year to date: -2.52%
• 1 year: 2.26%
• 5 years: -19.51%
• 10 years: -25.16%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Employees: 2,800

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

82% more call options, than puts

Call options by funds: $28.9M | Put options by funds: $15.9M

50% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 9 (+3) [Q3]

38% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 56

5% more funds holding

Funds holding: 447 [Q2] → 468 (+21) [Q3]

1.13% more ownership

Funds ownership: 92.27% [Q2] → 93.4% (+1.13%) [Q3]

3% more capital invested

Capital invested by funds: $6.21B [Q2] → $6.42B (+$207M) [Q3]

3% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 156

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $162 31% upside
• Avg. target: $184 49% upside
• High target: $207 67% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler David Amsellem 46% 1-year accuracy 17 / 37 met price target	32% upside $163	Overweight Reiterated	12 Dec 2024
RBC Capital Gregory Renza 37% 1-year accuracy 30 / 82 met price target	45% upside $179	Outperform Reiterated	12 Dec 2024
Needham Ami Fadia 32% 1-year accuracy 49 / 154 met price target	67% upside $207	Buy Reiterated	12 Dec 2024
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target	62% upside $200	Buy Reiterated	22 Nov 2024
Baird Joel Beatty 48% 1-year accuracy 21 / 44 met price target	31% upside $162	Outperform Maintained	18 Nov 2024